A Phase 2 interventional study of Placebo and Enicepatide in Obesity and Overweight, sponsored by Carmot Therapeutics, Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.
Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 8th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Taiwan, United Kingdom
Ages 40+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 469 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 300 across the 21 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Carmot Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Carmot Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
3 of the studies in Obesity by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT07499050Hoffmann-La RocheA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight | 2027-01-09 |
| NCT07589686Hoffmann-La RocheA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Obesity by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo administered subcutaneously (SC) once weekly.
Drug: Placebo
Enicepatide Dose Level 1 administered SC once weekly.
Drug: Enicepatide
Enicepatide Dose Level 2 administered SC once weekly.
Drug: Enicepatide
Enicepatide Dose Level 3 administered SC once weekly.
Drug: Enicepatide
Enicepatide Dose Level 4 administered SC once weekly.
Drug: Enicepatide
Enicepatide Dose Level 5 administered SC once weekly.
Drug: Enicepatide
Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Also known as: CT-388, RO7795068, RG6640
Percent Change in Body Weight from Baseline to Week 48
Time frame: Baseline to Week 48
Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 48
Time frame: Baseline and Week 48
Absolute Change in Body Weight (kg) from Baseline to Week 48
Time frame: Baseline to Week 48
Percent Change in Body Weight from Baseline to Week 48 by Obesity Class
Time frame: Baseline to Week 48
Change in Body Mass Index (BMI) from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Waist Circumference from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Hip Circumference from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Waist-to-Hip Ratio from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Waist-to-Height Ratio from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Fasting Plasma Glucose from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Fasting Insulin from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Fasting C-peptide from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from Baseline to Week 48
Time frame: Baseline to Week 48
Change in Quantitative Insulin Sensitivity Check Index (QUICKI) from Baseline to Week 48
Time frame: Baseline to Week 48
Percentage of Participants with Shift in Glycemic Status from Baseline to Week 48, Based on Fasting Plasma Glucose and HbA1c
Time frame: Baseline and Week 48
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Dec 2025, 15 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 15 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enicepatide